A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses ofAG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1Diabetes Mellitus (T1D).

Project: Research project

Description

A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1 Diabetes Mellitus (T1D).
StatusActive
Effective start/end date7/1/187/31/22

Funding

  • Intrexon Corporation

Fingerprint

Type 1 Diabetes Mellitus
Safety
teplizumab